Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effects of octreotide in a patient with parathyroid carcinoma
Autore:
Ybarra, J; Moises, J; Torregrosa, JV; Madhun, ZT; Schumacher, OP;
Indirizzi:
Hosp Clin Barcelona, Unidad Trasplante Renal, E-08036 Barcelona, Spain Hosp Clin Barcelona Barcelona Spain E-08036 al, E-08036 Barcelona, Spain Univ Hosp Cleveland, Div Clin Mol Endocrinol, Cleveland, OH 44106 USA UnivHosp Cleveland Cleveland OH USA 44106 rinol, Cleveland, OH 44106 USA
Titolo Testata:
NEFROLOGIA
fascicolo: 4, volume: 21, anno: 2001,
pagine: 406 - 410
SICI:
0211-6995(200107/08)21:4<406:EOOIAP>2.0.ZU;2-U
Fonte:
ISI
Lingua:
SPA
Soggetto:
HORMONE-RELATED PEPTIDE; PRIMARY HYPERPARATHYROIDISM; INTRACTABLE HYPERCALCEMIA; SOMATOSTATIN; SECRETION; TUMOR;
Keywords:
PTH carcinoma; hypercalcemia; urinary calcium excretion; octreotide;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Torregrosa, JV Hosp Clin Barcelona, Unidad Trasplante Renal, E-08036 Barcelona, Spain Hosp Clin Barcelona Barcelona Spain E-08036 celona, Spain
Citazione:
J. Ybarra et al., "Effects of octreotide in a patient with parathyroid carcinoma", NEFROLOGIA, 21(4), 2001, pp. 406-410

Abstract

Parathyroid carcinoma (PC) is a rare endocrine tumor whose management is difficult whenever surgery does not achieve complete en bloc resection or recurrence is detected. Medical options (mainly bisphosphonates) are scanty and often associated with toxic side-effects. We present a case report of a patient with recurrent PC after two surgical interventions who was treated with octreotide (SMS-201) taken into account the positive somatostatin staining of the specimen obtained during the last surgery. Short term effects (-2 weeks-) included a decrease in urinary calcium excretion paired with a simultaneous increase in urinary phosphorus excretion. Later on, continuous subcutaneous octreotide administration kept urinary calcium excretion at low levels and this effect was completely reversible/reinducible upon discontinuation/reintroduction of the drug. Neither iPTH nor total serum calcium were modified at short or long term basis. The lack of clear-cut therapeuticeffects make this findings a pure clinical observation. Thus, octreotide cannot be recommended for the treatment of parathyroid carcinoma.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 16:27:26